1. Home
  2. Company Research
  3. LivaNova PLC

LivaNova PLC Company Analysis & Research

LivaNova advances patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies. The company delivered double-digit revenue growth in 2025 with full-year revenue of $1.39 billion, increasing 10.7% on an organic basis. With operations in over 100 countries and strategic expansion into emerging markets like obstructive sleep apnea, the company is positioned as a market leader in critical care and neuromodulation.

LivaNova is pursuing strategic growth in high-growth segments such as obstructive sleep apnea and digital health for neuromodulation, while maintaining durable market share and profit gains in core Cardiopulmonary and Epilepsy businesses. The company is investing in advanced R&D, digital capabilities with FDA-approved platforms, and scaling next-generation manufacturing while deleveraging its balance sheet.

Company Overview

Founded: 2015. Headquarters: London, United Kingdom. Revenue: $1.39B. Employees: 3,300. Market Cap: $3.84B. Ticker: LIVN (NASDAQ).

Industry

Medical Devices - Cardiac Surgery & Neuromodulation

Cyborg Score: 7/10 — Solid

Growth drivers include ongoing strength in cardiopulmonary and epilepsy businesses, new product launches, entry into the obstructive sleep apnea market, and reimbursement improvements.

Full-year 2025 adjusted diluted earnings per share of $3.90 with Q4 strong performance suggests operational execution. The company completed early repayment of $200M in term facilities and $58M in convertible notes, with full repayment of remaining debt in January 2026. However, valuation compression is likely as growth moderates and R&D costs rise.

Key Strategic Insights for LivaNova PLC

  • CMS increased reimbursement for VNS Therapy for Drug-Resistant Epilepsy effective January 1, 2026, significantly reducing a known barrier to procedure penetration.
  • FDA approved LivaNova's cloud-based digital health platform for epilepsy, establishing the foundation for a Connected Care roadmap with initial clinician portal rollout.
  • 2026 includes manufacturing scale-up of next-generation oxygenator, OSA clinical trial device PMA approval, and CMS reimbursement reconsideration submission for difficult-to-treat depression.
  • Significant debt reduction with full repayment of remaining term facilities in January 2026, improving financial flexibility.

Recent Developments

  • (Feb 2026) Q4 2025 earnings show 9.5% organic growth; issued 6-7% 2026 revenue guidance
  • (Jan 2026) Completed full repayment of remaining term facilities; RECOVER durability study published showing 80% maintained benefit through 24 months
  • (Dec 2025) Appointed Lucile Blaise as Global Head of Commercialization for Obstructive Sleep Apnea
  • (Jan 2026) CMS approved higher reimbursement rates for VNS Therapy epilepsy procedures effective January 1

Competitors & Competitive Landscape

  • Medtronic — Diversified medical device leader with cardiac surgery portfolio
  • Boston Scientific — Offers competing neuromodulation solutions
  • Abbott Laboratories — Cardiovascular device manufacturer

Increased competition risks are noted in the field, with valuation compression expected as growth moderates. Main competitive risks include supply chain constraints and slow penetration rates in new markets. LivaNova competes in cardiac surgery devices and neuromodulation therapy against larger diversified medical device companies.

More Company Research

NDL Ventures Limited (formerly Hinduja Ventures Limited / NXTDIGITAL Limited) HF Foods Group, Inc. Honda India Power Products Limited Star Group, L.P. Bahnhof AB (publ) SKF India Limited Okumura Corporation Tata Chemicals Limited Lagardère S.A. Muyuan Foods Co., Ltd. Valley National Bancorp Dayforce, Inc. TechnipFMC plc National Bank of Canada Ayr Wellness

Full Company Research Reports

Looking for a more in-depth analysis of LivaNova PLC? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.

AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, and analyst podcasts.